To Get More Information on Liver Biopsy Market - Request Sample Report
The Liver Biopsy Market size was valued at USD 0.90 billion in 2023 and is estimated to reach USD 1.65 billion by 2032, with a growing CAGR of 6.99% over the forecast period 2024-2032.
The development of liver disease and the rising number of biopsy procedures in the U.S. are expected to fuel growth in the liver biopsy market. According to the Centers for Disease Control and Prevention, around 3.9 million adults were diagnosed with liver disease in the U.S. Such alarming statistic highlights the urgent need for efficient diagnostic solutions; the diagnosis of different forms of liver diseases, including non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and cirrhosis, requires fundamental importance of using liver biopsy systems.
Improving consciousness of diseases of the liver among patients as well as clinicians has increased the demand for new sophisticated diagnostic techniques. The demands for more minimal invasive processes also contribute to the further enhancement of requirements that need more precise and minimally invasive techniques, such as elastography and other imaging technologies that allow for more accurate diagnoses with minimal risks of potential complications from traditional biopsies. Patients also choose a mode of minimally invasive procedures due to less recovery time, and recent surveys revealed that more than 70% of patients prefer such treatments.
Major market players in developed countries are in the lead in terms of the worldwide liver biopsy market with their innovative products and services. They are not only improving their prospects in the developed regions but also penetrating developing nations along with emerging economies where the demand for advanced diagnostic solutions is growing rapidly. This strategic effort at innovation and expansion is critical to meet the increasing demand for effective management of liver diseases. However, despite its positive growth curve, the sectors still face certain problems. Major limitations of market growth are the high costs of diagnostic devices and instruments, especially in cost-sensitive areas. The costs may deter access to advanced liver biopsy technology, thus affecting patient care services and outcomes.
The market for liver biopsy has excellent growth potential in the future, with a peaking tendency on the grounds of the increasing prevalence of liver diseases, ever-increasing demand for innovative diagnostic techniques, and collaboration between researchers, clinicians, and technologists. Against this backdrop, cost-related challenges need to be addressed to ensure ultimate patient care and utilize the effective use of the market.
Market Trends in Liver Biopsy Technology:
| Trend | Description | Implications for the Liver Biopsy Market |
|---|---|---|
| Advancements in Imaging | Use of ultrasound, CT, and MRI for guidance | Improved accuracy and reduced complications |
| Liquid Biopsy Development | Non-invasive testing using blood samples | Potential to reduce the need for traditional biopsy |
| Automation in Biopsy Devices | Introduction of automated biopsy systems | Increased efficiency and standardization |
| Enhanced Patient Safety | New protocols and technologies for risk reduction | Higher adoption rates among clinicians |
| Telemedicine Integration | Remote consultation for biopsy interpretation | Broader access to specialists and reduced patient burden |
Drivers
Transforming Liver Biopsy Technologies and Advancing Patient Care
Several key market drivers are impacting the advancement of liver biopsy systems. Advances in technology including elastography and advanced imaging reduce invasiveness while improving diagnostic accuracy, thus making procedures less hazardous for patients. According to WHO research, over 844 million have chronic liver diseases, which makes very precise diagnostic equipment a necessity. Given that conditions such as fatty liver disease and viral hepatitis are increasingly causing a global burden, the awareness and subsequently the demand for the systems for liver biopsies make them indispensable for the diagnosing of the said conditions. Furthermore, the patients are in larger numbers requiring less invasive procedures that result in reduced recovery time, creating a compulsion for the healthcare provider to innovate. It has recently been reported that more than 70% of patients prefer minimally invasive diagnostic options. The regulatory bodies also aim for more accurate, reliable, and standardized diagnostic methods, thereby prompting innovation in liver biopsy technologies.
Interdisciplinary approaches to finding solutions to these needs are fostered by the collaboration of researchers, clinicians, and technologists. Furthermore, chronic liver diseases continue to increase their prevalence, and more and more patients are generating the need for the improvement of diagnostic tools. According to estimated figures, one in four adults suffers from non-alcoholic fatty liver disease. Financial benefits for healthcare providers with efficient and cost-effective solutions also aid in the continuous evolution of liver biopsy systems to ensure optimal patient care and outcomes. All these diverse drivers are transforming the current landscape of liver biopsy technologies.
Restraints
Concerns Regarding Invasiveness and Interpretation Variability
Economic Barriers and Competition from Non-Invasive Alternatives
by Type
The percutaneous biopsy segment dominated the liver biopsy market, accounting for approximately 60% of the total market share in 2023. This technique is favored due to its minimally invasive nature, which allows for quick recovery and reduced patient discomfort. It utilizes imaging guidance to precisely target liver tissue, making it a preferred option for diagnosing liver conditions. Furthermore, advancements in imaging technologies have enhanced the accuracy and safety of percutaneous biopsies, contributing to its widespread acceptance.
The transjugular biopsy segment is projected to grow at the fastest rate, with an estimated growth rate of around 8% annually. This method is particularly beneficial for patients with coagulopathy or those at high risk of complications from percutaneous procedures. Its ability to obtain liver samples while minimizing bleeding risk makes it increasingly appealing to healthcare providers.
Do You Need any Customization Research on Liver Biopsy Market - Enquire Now
by Indication
The NAFLD segment held a significant share of the market, representing approximately 45% of the total indications for liver biopsy procedures in 2023. The rising prevalence of obesity and metabolic syndrome globally has contributed to the increased demand for diagnostic solutions related to NAFLD.
The autoimmune hepatitis segment is expected to grow the fastest, with a projected growth rate of 9% annually. As awareness of autoimmune diseases increases, more patients are being diagnosed, driving demand for accurate diagnostic methods such as liver biopsies.
by End User
The hospitals & Clinics segment was the largest in the liver biopsy market, accounting for about 70% of the market share in 2023. Hospitals and clinics are equipped with advanced diagnostic tools and skilled personnel, making them the primary locations for conducting liver biopsy procedures.
Diagnostic centers are emerging as the fastest-growing segment, with an estimated growth rate of 10% annually. The rise in outpatient diagnostics and the increasing focus on specialized facilities are propelling this growth. Diagnostic centers provide targeted services and can enhance access to liver biopsy procedures, making them an attractive option for patients and healthcare providers.
North America's liver biopsy market was the dominant region in 2023 with a 45.7% share because of technologically advanced health care in this region, which has an increasing population that suffers from liver diseases, such as alcoholic liver disease, as well as more healthcare spending. Government support for research and development initiatives will also fuel the expansion of this market. It is a major cause of mortality and morbidity in the Americas. The CDC reports that as many as 38,170 deaths were due to liver conditions in the year 2016, while nearly 6.10% of U.S. adults are reported to be diagnosed with some form of liver disease. Liver diseases accounted for approximately 4.5% of deaths in the United States in 2020, which further brings it to the forefront and highlights its crucial importance in public health.
Other significant markets in Europe include Germany, France, and the U.K., which are being fuelled by increased utilization of diagnostic services in tertiary care hospitals, the number of research and development activities related to chronic disease diagnosis, and the rise of new companies dealing with medical equipment. According to a 2022 report, nearly 30,000 deaths in the U.K. have been linked to liver disease, thereby depicting the same as an important health concern.
The Asia Pacific region is anticipated to grow with a high CAGR for the liver biopsy market, mainly due to the high growth rate of the healthcare industries in major economies such as China, Japan, and India. The regional market leader is Japan, driven by available technologies and increasing healthcare costs along with governmental support towards research. It is observed that nearly 25% of the population of Japan suffers from chronic liver diseases, such as hepatitis B and C. The country has a huge patient base suffering from chronic diseases and is witnessing substantial growth opportunities. The rapid advancement of healthcare technology and enhanced demand for superior-quality diagnostic devices are also likely to boost market growth in the region.
Key Players in the Liver Biopsy Market by Offering
1. Biopsy Devices and Instruments
Becton, Dickinson, and Company
C. R. Bard, Inc.
Argon Medical Devices, Inc.
2. Imaging and Guidance Technologies
Medtronic
Boston Scientific Corporation
Veran Medical
3. Diagnostic Solutions and Laboratories
Hologic, Inc.
Leica Biosystems
4. Innovative Technologies
Mauna Kea Technologies
Intact Medical Corp.
Fujifilm Medical Systems
5. Specialty and Emerging Players
RI.MOS.
INRAD Inc.
Recent Developments
Boston Scientific acquired Apollo Endosurgery in April 2023, expanding its portfolio of minimally invasive solutions for gastrointestinal disorders, including liver biopsies, which are crucial for diagnosing liver diseases.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 0.90 Billion |
| Market Size by 2032 | USD 1.65 Billion |
| CAGR | CAGR of 6.99% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Percutaneous, Transjugular, Laparoscopic) • By Indication (Non-alcoholic Fatty Liver Disease, Chronic Hepatitis B Or C, Autoimmune Hepatitis, Alcoholic Liver Disease, Others) • By End User (Hospitals & Clinics, Diagnostic Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia-Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia-Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Becton, Dickinson, and Company, Cook Medical, R. Bard, Inc., Argon Medical Devices, Inc., Medtronic, Boston Scientific Corporation, Veran Medical, MDxHealth, Hologic, Inc., Leica Biosystems, Mauna Kea Technologies, Intact Medical Corp., Fujifilm Medical Systems, Sterylab, MOS, INRAD Inc. and Others |
| Key Drivers | • Transforming Liver Biopsy Technologies and Advancing Patient Care |
| Restraints | • Concerns Regarding Invasiveness and Interpretation Variability • Economic Barriers and Competition from Non-Invasive Alternatives |
Liver Biopsy Market size was valued at USD 0.90 billion in 2023.
The CAGR growth rate of liver biopsy market is approx. CAGR of 6.99% over the forecast period 2024-2032.
The major key players, Becton, Dickinson and Company (BD), Cook Medical, Medtronic placebos Scientific Corporation, Olympus Corporation, Veran Medical Technologies, Aggrotech Pharmaceuticals, TSK Laboratory, Cardinal Health, SOMATEX Medical Technologies, Argon Medical Devices, Med axiom Corporation, Merit Medical Systems, Path Group, Others.
North America is dominating the market and will continue to dominate the market during the forecasted period
Global Healthcare of Liver biopsy Market is divided into four segments.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, by Region
6.2 Market Share Analysis, by Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Liver Biopsy Market Segmentation, by Type
7.1 Chapter Overview
7.2 Percutaneous
7.2.1 Percutaneous Market Trends Analysis (2020-2032)
7.2.2 Percutaneous Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Transjugular
7.3.1 Transjugular Market Trends Analysis (2020-2032)
7.3.2 Transjugular Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Laparoscopic
7.4.1 Laparoscopic Market Trends Analysis (2020-2032)
7.4.2 Laparoscopic Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Liver Biopsy Market Segmentation, by Indication
8.1 Chapter Overview
8.2 Non-alcoholic Fatty Liver Disease
8.2.1 Non-alcoholic Fatty Liver Disease Market Trends Analysis (2020-2032)
8.2.2 Non-alcoholic Fatty Liver Disease Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Chronic Hepatitis B Or C
8.3.1 Chronic Hepatitis B Or C Market Trends Analysis (2020-2032)
8.3.2 Chronic Hepatitis B Or C Market Size Estimates and Forecasts to 2032 (USD Million)
Autoimmune Hepatitis
8.4.1 Autoimmune Hepatitis Market Trends Analysis (2020-2032)
8.4.2 Autoimmune Hepatitis Market Size Estimates and Forecasts to 2032 (USD Million)
Alcoholic Liver Disease
8.4.1 Alcoholic Liver Disease Market Trends Analysis (2020-2032)
8.4.2 Alcoholic Liver Disease Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Liver Biopsy Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals & Clinics
9.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Diagnostic Centers
9.3.1 Diagnostic Centers Market Trends Analysis (2020-2032)
9.3.2 Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.4 North America Liver Biopsy Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.5 North America Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.6.2 USA Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.2.6.3 USA Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.7.2 Canada Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.2.7.3 Canada Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.8.2 Mexico Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.2.8.3 Mexico Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.5 Eastern Europe Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.6.2 Poland Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.6.3 Poland Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.7.2 Romania Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.7.3 Romania Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.8.2 Hungary Liver Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.3 Hungary Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.9.2 Turkey Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.9.3 Turkey Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.4 Western Europe Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.5 Western Europe Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.6.2 Germany Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.6.3 Germany Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.7.2 France Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.7.3 France Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.8.2 UK Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.8.3 UK Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.9.2 Italy Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.9.3 Italy Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.10.2 Spain Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.10.3 Spain Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.11.3 Netherlands Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.12.3 Switzerland Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.13.2 Austria Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.13.3 Austria Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.4 Asia Pacific Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.5 Asia Pacific Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.6.2 China Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.6.3 China Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.7.2 India Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.7.3 India Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.8.2 Japan Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.8.3 Japan Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.9.2 South Korea Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.9.3 South Korea Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.10.2 Vietnam Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.10.3 Vietnam Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.11.2 Singapore Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.11.3 Singapore Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.12.2 Australia Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.12.3 Australia Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.4 Middle East Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.5 Middle East Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.6.2 UAE Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.6.3 UAE Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.7.2 Egypt Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.7.3 Egypt Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.9.2 Qatar Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.9.3 Qatar Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.4 Africa Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.5 Africa Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.6.2 South Africa Liver Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.3 South Africa Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.7.3 Nigeria Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Liver Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.4 Latin America Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.5 Latin America Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.6.2 Brazil Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.6.3 Brazil Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.7.2 Argentina Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.7.3 Argentina Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.8.2 Colombia Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.8.3 Colombia Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Liver Biopsy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Liver Biopsy Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Liver Biopsy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Becton, Dickinson, and Company
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 MDxHealth
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Veran Medical
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Medtronic
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Argon Medical Devices, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Mauna Kea Technologies
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Boston Scientific Corporation
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Intact Medical Corp.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 C. R. Bard, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Cook Medical
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
Percutaneous
Transjugular
Laparoscopic
By Indication
Non-alcoholic Fatty Liver Disease
Chronic Hepatitis B Or C
Autoimmune Hepatitis
Alcoholic Liver Disease
Others
By End User
Hospitals & Clinics
Diagnostic Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
Chromatography Software Market was valued at $ 1.15 billion in 2023 and is expected to reach $ 2.62 billion by 2032, growing at a CAGR of 9.62% from 2024-2032.
The Health Insurance Exchange Market Size was valued at USD 2553.96 Billion in 2023 and is expected to reach USD 5,751.80 Billion by 2032 and grow at a CAGR of 9.91% over the forecast period 2024-2032.
The Telerehabilitation Market Size was valued at USD 3.4 billion in 2023, and is expected to reach USD 12.34 billion by 2032, and grow at a CAGR of 15.4% over the forecast period 2024-2032.
The Softgel Capsule Market Size was valued USD 8.18 billion in 2023 and is expected to reach $14.06 billion by 2031 and grow at a CAGR of 7% by 2024-2031.
The Alzheimer’s Therapeutics Market Size was valued at USD 3.78 Billion in 2023 and will reach USD 13.42 Billion by 2032, with a growing CAGR of 15.14% during 2024-2032.
Knee Replacement Market was valued at USD 9.78 billion in 2023 and is expected to reach USD 12.76 billion by 2032, growing at a CAGR of 3% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
